You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

9 Results
Regimen
Statistical Reports
*/ For the most recent data, refer to the Ontario Cancer Screening Performance Report 2023.
May 2017
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - Maintenance Treatment for Refractory Follicular Lymphoma
Dec 2019
Guidelines and Advice
Apr 2019
Guidelines and Advice
Status: Current
Version: N/A
Aug 2019
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: N/A
Version: N/A
Oct 2019